Trial blazers

Amid the chaos of Brexit, pioneering clinical research continues defiantly, plotting its way through the complexity of disease and providing patients with the currencies of hope, transformation and reinvention.
Turning the tide

Paul Midgley, of Wilmington Healthcare, explores the NHS’ strategy for tackling cardiovascular disease and what these new approaches mean for pharma
Driving change

Gilead Sciences’ Alex Kalomparis says pharma has a role to play in supporting social change and must not shy away from it

News

View all

BMS’ Opdivo, Yervoy show promise in lung cancer

The results build on the benefits the combination has previously shown in various indications.

23rd October 2019

Electronic prescriptions could save NHS £300m

The final roll-out phase is set to go live on November 18th.

23rd October 2019

Stelara bags positive results in ulcerative colitis

The data were presented at the United European Gastroenterology Week (UEGW) congress.

23rd October 2019

Success for early MLD gene therapy

The treatment is a cryopreserved formulation of OTL-200.

23rd October 2019

Janssen seeks to expand Tremfya in arthritis

Up to a third of the 14 million people who are living with psoriasis in Europe will also develop psoriatic arthritis.

23rd October 2019

Web Exclusives

View all

Medicines optimisation - transforming one of healthcare's biggest spends

Orlando Agrippa on how we can achieve better medicines optimisation and how this will reap rewards for everyone

Fostering a ‘golden era’ of medicines innovation

Cooperation and collaboration between the NHS, government and industry will be key to turbocharging the discovery and delivery of a new wave of medical innovations for patients, says Haseeb Ahmad, managing director UK, Ireland and Nordics at Novartis Pharmaceuticals and Country President, Novartis UK.

Keep on preparing for Brexit

How can the pharma industry best prepare for Brexit?

Engaging with patient advocacy groups

Harrison Gaiger, marketing manager of the Research Partnership, says working with patient advocacy groups is key to conducting effective rare disease research

Magazine

View more from the latest edition

Turning the tide

Paul Midgley, of Wilmington Healthcare, explores the NHS’ strategy for tackling cardiovascular disease and what these new approaches mean for pharma

Driving change

Gilead Sciences’ Alex Kalomparis says pharma has a role to play in supporting social change and must not shy away from it

Opening doors

China’s pharmaceutical market increasingly offers opportunities for UK drugmakers

Advancing patient engagement

Neil McGregor-Paterson explores whether health technology assessment is leading the field in meaningful patient involvement

Trial blazers

Amid the chaos of Brexit, pioneering clinical research continues defiantly, plotting its way through the complexity of disease and providing patients with the currencies of hope, transformation and reinvention.